Cart
sales@molnova.com
C188-9 (b)
CAS No. 425373-68-8
C188-9 (b)( C 188-9 )
Catalog No. M14443 CAS No. 425373-68-8
A novel small-molecule STAT3 inhibitor with Ki of 12.4 nM; inhibits STAT3 binding to its pY-peptide ligand.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameC188-9 (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel small-molecule STAT3 inhibitor with Ki of 12.4 nM; inhibits STAT3 binding to its pY-peptide ligand.
-
DescriptionA novel small-molecule STAT3 inhibitor with Ki of 12.4 nM; inhibits STAT3 binding to its pY-peptide ligand, suppresses cytokine-stimulated pSTAT3, reduces constitutive pSTAT3 activity, and inhibits anchorage dependent and independent growth of in multiple HNSCC cell lines; prevents tumor xenograft growth, modulates many STAT3-regulated genes involved in oncogenesis and radioresistance in vivo.Solid Tumors Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsC 188-9
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number425373-68-8
-
Formula Weight469.555
-
Molecular FormulaC28H23NO4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN-(1',2-dihydroxy-[1,2'-binaphthalen]-4'-yl)-4-ethylbenzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Redell MS, et al. Blood. 2011 May 26;117(21):5701-9.
2. Bharadwaj U, et al. Oncotarget. 2016 May 3;7(18):26307-30.
3. Jung KH, et al. Clin Cancer Res. 2017 Sep 15;23(18):5537-5546.
4. Minus MB, et al. Angew Chem Int Ed Engl. 2015 Oct 26;54(44):13085-9.
molnova catalog
related products
-
Hydrazinocurcumin
Hydrazinocurcumin is a synthetic curcumin derivative that inhibits the proliferation of bovine aortic endothelial cells (BAECs) with IC50 of 520 nM without cytotoxicity.
-
Artesunate
Artesunate is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69.
-
MMPP
MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.
